• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Amber Specialty is Chosen to Dispense Livtencity


Livtencity, manufactured by Takeda, was approved in November 2021 and is the first therapy to treat cytomegalovirus infection after transplants.

Amber Specialty Pharmacy has been chosen to dispense Livtencity (maribavir), the first and only treatment indicated for the treatment patients 12 years of age and older with post-transplant cytomegalovirus (CMV) infection. Amber Specialty Pharmacy is licensed in all 50 states, as well as Puerto Rico.

Kristin Williams

Kristin Williams

“The transplant community has been at the heart of everything we do since the day we opened our doors, and it continues to be a vital pillar of our organization,” Kristin Williams, president of Amber Specialty Pharmacy, said in a statement.

Livtencity, manufactured by Takeda, was approved in November 2021 based on phase 3 data that showed, of the 235 patients who received Livtencity, 56% had levels of CMV DNA concentration levels below what was measurable versus 24% of the 117 patients who received an investigator-assigned treatment.

Livtencity is a new molecular entity that targets CMV at pUL97, resulting in inhibition of viral DNA replication.

CMV is a beta herpesvirus that commonly infects humans and typically resides latent and asymptomatic in the body but may reactivate during periods of immunosuppression. Serious disease may occur in individuals with compromised immune systems.

CMV is one of the most common infections experienced by transplant recipients, with an estimated incidence rate of around 16% to 56% in solid organ transplants and 30% to 70% in hematopoietic stem cell transplants.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.